CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 210 enrolled / 210 target
Drug / intervention
Pembrolizumab, Sintilimabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05549037
NCT05549037Phase 3CompletedOn Track (4.6/mo)Completion was 18mo ago
CompareCT.gov

Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial

Hunan Province Tumor Hospital·interventional·Posted Sep 22, 2022·Updated Jun 3, 2026

In Brief

A Phase 3 clinical trial evaluating Pembrolizumab, Sintilimab for Non-small Cell Lung Cancer. Completed, enrolled 210 participants across 1 site.

Detailed Summary

This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedSep 22, 2022
Enrollment StartSep 23, 2022
Primary CompletionDec 2, 2024
Study CompletionApr 30, 2026
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 3.8 years ago

Arms & Interventions

Arm A: Morning groupexperimental

All the patients in this arm will be treated with immunochemotherapy before 15:00.

Drug: Pembrolizumab, Sintilimab
Arm B: Afternoon groupexperimental

All the patients in this arm will be treated with immunochemotherapy after 15:00.

Drug: Pembrolizumab, Sintilimab

Interventions

Pembrolizumab, Sintilimabdrug

One for morning group, the patients in this group were treated with immunochemotherapy before 15:00. One for afternoon group, the patients in this group were treated with immunochemotherapy after 15:00.